Management of the myeloproliferative disorders : distinguishing data from dogma.
Green
Anthony R
AR
University Department of Haematology, Cambridge, UK.
Vassiliou
George S
GS
Curtin
Natasha
N
Campbell
Peter J
PJ
D000014:Abnormalities, Drug-Induced / Q000209:etiology / Q000517:prevention & control; D000328:Adult; D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use; D000075202:Contraindications; D005260:Female; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D016898:Interferon-alpha / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009196:Myeloproliferative Disorders / Q000175:diagnosis / Q000628:therapy*; D018962:Phlebotomy; D011087:Polycythemia Vera / Q000175:diagnosis / Q000401:mortality / Q000628:therapy; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000188:drug therapy; D011379:Prognosis; D011799:Quinazolines / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D013920:Thrombocythemia, Essential / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy; D019851:Thrombophilia / Q000188:drug therapy / Q000209:etiology
D000925:Anticoagulants; D016898:Interferon-alpha; D011799:Quinazolines; C021139:anagrelide; D006918:Hydroxyurea